Latest App Notes & Case Studies

In biotherapeutic development, decreased drug doses and limited sample volumes require higher quantification sensitivity, while the complexity of biological matrices calls for the need of assay selectivity improvement.

It has proven difficult to accurately identify the biological targets of cancer, which are necessary for the development of successful therapeutics including novel immunotherapies, such as those based on chimeric antigen receptor (CAR) T cells.

One approach to develop drugs for infectious diseases involves a comprehensive understanding of human-pathogen protein interactions, as targeting host proteins helps reduce the possibility of drug resistance by creating a more significant evolutionary barrier for the virus.

Download this app note to discover reasons why you should consider fully automated enzyme analysis.

The clinical success of CAR T-cell therapy has spurred increased interest and investments in the advanced therapeutics industry.

Surface plasmon resonance (SPR) is a core technology used in many pharma and biotechnology settings for this purpose, however traditional initial SPR screening of weak affinity compounds using a single fixed concentration injection can present numerous challenges.

Comprehensive disease modeling can be challenging for many labs due to variations in reagents, cell culture conditions, technical inconsistencies across protocols and experiments and bandwidth limitations.

In recent years, interest in lipid nanoparticle (LNP) research has increased due to promising opportunities for RNA-based therapy and gene-editing technology, and LNPs are showing promise as nucleic acid delivery vehicles in the pharmaceutical industry.

Expansion of Specific Lymphocyte Populations With 4Cell® Nutri-T Xeno-Free, Serum-Free Medium

The success of CAR T-cell therapy requires efficient expansion of specific subpopulations of patient-derived immune cells.

Various autoimmune diseases (e.g., myasthenia gravis) are mediated by IgG autoantibodies. To address this mechanism of autoimmunity, researchers are exploring the therapeutic use of FcRn inhibitors in an effort to decrease the pathogenesis of IgG and develop new therapies.